Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFXS | ISIN: US2210151005 | Ticker-Symbol: C17
Tradegate
17.09.25 | 13:00
4,905 Euro
0,00 % 0,000
1-Jahres-Chart
CORVUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CORVUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,8604,97508:03
4,8654,98007:47

Aktuelle News zur CORVUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.Corvus Pharmaceuticals GAAP EPS of -$0.10 beats by $0.032
CORVUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
07.08.Corvus Pharmaceuticals, Inc. - 8-K, Current Report1
31.07.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 20256
25.06.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis207SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted...
► Artikel lesen
13.06.Corvus Pharmaceuticals, Inc. - 8-K, Current Report2
04.06.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis253Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3...
► Artikel lesen
04.06.Corvus Pharmaceuticals, Inc. - 8-K, Current Report2
20.05.Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating5
09.05.Why Is Corvus Pharmaceuticals Stock Soaring On Friday?4
09.05.Corvus Pharmaceuticals shares surge on positive trial results1
09.05.Corvus Pharmaceuticals-Aktien steigen nach positiven Studienergebnissen2
09.05.Pre-market Movers: ZK International, Jade Biosciences, Twin Vee Powercats, Corvus Pharmaceuticals, Iovance Biotherapeutics1.329OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green ZK International Group Co., Ltd. (ZKIN) is up over...
► Artikel lesen
09.05.Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected3
08.05.Corvus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
08.05.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results162Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts...
► Artikel lesen
08.05.Corvus Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
23.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 20251
09.04.Corvus Pharmaceuticals, Inc. - 8-K, Current Report3
09.04.Corvus Pharmaceuticals expands board with new director1
09.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors1
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1